The National Committee for Quality Assurance, a nonprofit group that accredits health plans and care providers, has started evaluating disease management companies.
The identification of effective DED treatment strategies is hindered by the lack of an accepted set of definitive criteria for evaluating disease severity.
Tumor volume is considered useful in evaluating disease progression and response to therapy, and in assessing the need for changes in treatment plans.
These preliminary data suggest that 18F- FDG PET/CT is a reproducible and accurate tool for evaluating disease activity in refractory rheumatoid arthritis and its non-response to rituximab.
As these trials approach completion, rheumatologists can anticipate an increased demand for expertise and experience in evaluating disease progression and treatment response with these techniques and the emergence of MRI systems specifically designed for this market.
Especially in remote areas, where there is a lack of medical resources, an easy-to-use tool such as the one in the present study for detecting and evaluating disease conditions is needed.
These preliminary results support the proof of concept but larger series are obviously needed to confirm the clinical relevance of this technology in rheumatoid arthritis, These preliminary data suggest that 18F- FDG PET/CT is a reproducible and accurate tool for evaluating disease activity in refractory rheumatoid arthritis and its non-response to rituximab.
Finally, it is simple to construct the stRRF for evaluating disease risk under different conditions and easily extended to other new functions such as excess risk function.
In evaluating disease burden, we relied on estimates from the World Health Organization for DALYs as opposed to quality-adjusted life years, which are frequently used in pharmacoeconomic analyses.
However, a framework of how to assess fully whether such genetic information might help improve the clinical management of patients remains unclear, especially when compared to laboratory markers that are considered the gold standard in evaluating disease prognosis.
We take this approach to evaluating disease control strategies in an urban setting (31 ).
